Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy |
Hong, Beom-Ju
(Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology)
Kim, Jeongwoo (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Jeong, Hoibin (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Bok, Seoyeon (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Kim, Young-Eun (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Ahn, G-One (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) |
1 | Wittenborn TR, Horsman MR. Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy. Acta Oncol 2015;54:1385-92. DOI |
2 | Nori D, Cain JM, Hilaris BS, Jones WB, Lewis JL Jr. Metronidazole as a radiosensitizer and high-dose radiation in advanced vulvovaginal malignancies, a pilot study. Gynecol Oncol 1983;16:117-28. DOI |
3 | Schlaff CD, Krauze A, Belard A, O'Connell JJ, Camphausen KA. Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiat Oncol 2014;9:88. DOI |
4 | Schuler E, Trovati S, King G, et al. Experimental platform for ultra-high dose rate FLASH irradiation of small animals using a clinical linear accelerator. Int J Radiat Oncol Biol Phys 2016 Sep 20. [Epub]. http://dx.doi.org/10.1016/j.ijrobp.2016.09.018. DOI |
5 | Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;72:967-71. DOI |
6 | Park J, Lee J, Kwag J, et al. quantum dots in an amphiphilic polyethyleneimine derivative platform for cellular labeling, targeting, gene delivery, and ratiometric oxygen sensing. ACS Nano 2015;9:6511-21. DOI |
7 | Favaudon V, Caplier L, Monceau V, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med 2014;6:245ra93. DOI |
8 | Palmer GM, Vishwanath K, Dewhirst MW. Application of optical imaging and spectroscopy to radiation biology. Radiat Res 2012;177:365-75. DOI |
9 | Vishwanath K, Klein D, Chang K, Schroeder T, Dewhirst MW, Ramanujam N. Quantitative optical spectroscopy can identify long-term local tumor control in irradiated murine head and neck xenografts. J Biomed Opt 2009;14:054051. DOI |
10 | Kersey FR, Zhang G, Palmer GM, Dewhirst MW, Fraser CL. Stereocomplexed poly(lactic acid)-poly(ethylene glycol) nanoparticles with dual-emissive boron dyes for tumor accumulation. ACS Nano 2010;4:4989-96. DOI |
11 | Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014;508:269-73. DOI |
12 | Prasad P, Gordijo CR, Abbasi AZ, et al. Multifunctional albumin-MnO(2) nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. ACS Nano 2014;8:3202-12. DOI |
13 | Song X, Feng L, Liang C, Yang K, Liu Z. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Lett 2016;16:6145-53. DOI |
14 | Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3. |
15 | Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49. DOI |
16 | Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650-6. DOI |
17 | Nozue M, Lee I, Yuan F, et al. Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J Surg Oncol 1997;66:30-8. DOI |
18 | Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47. DOI |
19 | Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007;67:7646-53. DOI |
20 | Hammond EM, Giaccia AJ. Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? Clin Cancer Res 2006;12:5007-9. DOI |
21 | Jeong H, Bok S, Hong BJ, Choi HS, Ahn GO. Radiation-induced immune responses: mechanisms and therapeutic perspectives. Blood Res 2016;51:157-63. DOI |
22 | Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704. DOI |
23 | Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014;211:781-90. DOI |
24 | Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2005;33:47-63. DOI |
25 | Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-54. DOI |
26 | Dische S. Local tumour control and its effect upon survival of the patient. Australas Radiol 1983;27:181-5. DOI |
27 | Chaplin DJ, Durand RE, Stratford IJ, Jenkins TC. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys 1986;12:1091-5. DOI |
28 | Rockwell S. Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res 1997;9:383-90. |
29 | Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912-8. DOI |
30 | Sun X, Xing L, Ling CC, Li GC. The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging. Int J Hyperthermia 2010;26:224-31. DOI |
31 | Adams GE, Cooke MS. Electron-affinic sensitization. I: A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol Relat Stud Phys Chem Med 1969;15:457-71. DOI |
32 | Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol 1985;3:97-115. DOI |
33 | Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci 2007;12:3483-501. DOI |
34 | Lee DJ, Cosmatos D, Marcial VA, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-76. DOI |
35 | Brown JM, Yu NY, Brown DM, Lee WW. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 1981;7:695-703. DOI |
36 | Saunders MI, Anderson PJ, Bennett MH, et al. The clinical testing of Ro 03-8799: pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys 1984;10:1759-63. DOI |
37 | Coleman CN, Hirst VK, Brown DM, Halsey J. The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies. Int J Radiat Oncol Biol Phys 1984;10:1381-6. DOI |
38 | Smithen CE, Clarke ED, Dale JA, et al. Novel (nitro-1-imidazolyl) alkanolamines as potential radiosensitisers with improved therapeutic properties. In: Brady LW, editor. Radiation sensitizers: their use in the clinical management of cancer. New York: Masson Publishing Inc.; 1980. p. 22-32. |
39 | Dische S, Machin D, Chassange D. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993;26:93-103. DOI |
40 | Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32. DOI |
41 | Dische S, Saunders MI, Lee ME, Adams GE, Flockhart IR. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer 1977;35:567-79. DOI |
42 | Rofstad EK. Radiation response of the cells of a human malignant melanoma xenograft. Effect of hypoxic cell radiosensitizers. Radiat Res 1981;87:670-83. DOI |
43 | Song C, Hong BJ, Bok S, et al. Real-time tumor oxygenation changes after single high-dose radiation therapy in orthotopic and subcutaneous lung cancer in mice: clinical implication for stereotactic ablative radiation therapy schedule optimization. Int J Radiat Oncol Biol Phys 2016;95:1022-31. DOI |
44 | Kelada OJ, Decker RH, Zheng MQ, et al. Quantification of tumor hypoxia in lung cancer patients undergoing stereotactic body radiotherapy using dynamic PET imaging. In: 15th International Congress of Radiation Research (ICRR) Annual Meeting; 2015 May 25-29; Kyoto, Japan. |
45 | Siemann DW, Hill SA. Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination. Cancer Res 1986;46:629-32. |
46 | Palcic B, Faddegon B, Skarsgard LD. The effect of misonidazole as a hypoxic radiosensitizer at low dose. Radiat Res 1984;100:340-7. DOI |
47 | Karasawa K, Sunamura M, Okamoto A, et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebocontrolled randomised study. Radiother Oncol 2008;87:326-30. DOI |
48 | Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95. DOI |
49 | Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410. DOI |
50 | Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998;253:743-50. DOI |
51 | Brown JM. The hypoxic cell: a target for selective cancer therapy: eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-70. |
52 | Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol 2006;1:71-9. DOI |
53 | Fleming IN, Manavaki R, Blower PJ, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer 2015;112:238-50. DOI |
54 | Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104. DOI |
55 | Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009;172:653-65. DOI |
56 | Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16. DOI |
57 | Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008;70:1219-28. DOI |
58 | Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 2009;69:383-92. DOI |
59 | Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972;105:135-42. DOI |
60 | Timmerman RD. Surgery versus stereotactic body radiation therapy for early-stage lung cancer: who's down for the count? J Clin Oncol 2010;28:907-9. DOI |
61 | Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011;79:1188-95. DOI |
62 | Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6. DOI |
63 | Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-31. DOI |